New Therapeutic Strategies for Lung Cancer

Icard, Philippe; Damotte, Diane; Alifano, Marco

doi:10.3390/cancers13081937

Cited by 7 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discovery of specific epidermal growth factor receptor (EGFR)-activating mutations has transformed NSCLC therapy. Because of their excellent performance, EGFR-tyrosine kinase inhibitors (TKIs) have become the first-line treatment for patients with EGFR mutations [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer

et al. 2023

View full text Add to dashboard Cite

Lung cancer (LC) is considered as one of the leading causes of cancer-associated mortalities. Cancer cells’ reprogrammed metabolism results in changes in metabolite concentrations, which can be utilized to identify a distinct metabolic pattern or fingerprint for cancer detection or diagnosis. By detecting different metabolic variations in the expression levels of LC patients, this will help and enhance early diagnosis methods as well as new treatment strategies. The majority of patients are identified at advanced stages after undergoing a number of surgical procedures or diagnostic testing, including the invasive procedures. This could be overcome by understanding the mechanism and function of differently regulated metabolites. Significant variations in the metabolites present in the different samples can be analyzed and used as early biomarkers. They could also be used to analyze the specific progression and type as well as stages of cancer type making it easier for the treatment process. The main aim of this review article is to focus on rewired metabolic pathways and the associated metabolite alterations that can be used as diagnostic and therapeutic targets in lung cancer diagnosis as well as treatment strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In a significant number of lung cancer patients, the tumor cells metastasize to other organs, largely to lymph nodes, bones, adrenal glands, and the brain [ 17 , 18 , 19 , 20 ]. Notably, the tumor type and stages of the cancer are used to determine the prognosis and treatment options [ 21 , 22 ]. In early-stage NSCLC, lobectomy is a preferred choice of treatment [ 21 , 23 , 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer

Sirhan,

Alojair,

Thyagarajan

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Lung cancer remains one of the major human malignancies affecting both men and women worldwide, with non-small cell lung cancer (NSCLC) being the most prevalent type. Multiple mechanisms have been identified that favor tumor growth as well as impede the efficacy of therapeutic regimens in lung cancer patients. Among tumor suppressor genes that play critical roles in regulating cancer growth, the phosphatase and tensin homolog (PTEN) constitutes one of the important family members implicated in controlling various functional activities of tumor cells, including cell proliferation, apoptosis, angiogenesis, and metastasis. Notably, clinical studies have also documented that lung tumors having an impaired, mutated, or loss of PTEN are associated with low survival or high tumor recurrence rates. To that end, PTEN has been explored as a promising target for anti-cancer agents. Importantly, the ability of PTEN to crosstalk with several signaling pathways provides new approaches to devise effective treatment options for lung cancer treatment. The current review highlights the significance of PTEN and its implications in therapeutic approaches against NSCLC.

show abstract

“…It usually evolves from the mucosal glands. When feasible, complete tumoral resection is considered the best treatment option; however, targeted therapies (mainly tyrosine kinase inhibitors) and immunotherapies may induce clinical responses in suitable patient subgroups [ 3 ]. In sharp contrast to adenocarcinoma (ADC), Pulmonary Sarcomatoid Carcinoma (PSC) is a rare (0.3% to 1% of all pulmonary malignancies) category of highly aggressive and poorly differentiated tumors with poor prognosis and few treatment options, as patients show limited response or resistance to conventional chemotherapy [ 4 , 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma

Lázaro

Lorz

Enguita

et al. 2022

Cancers

View full text Add to dashboard Cite

Lung cancer remains the leading cause of cancer deaths worldwide. Among the Non-Small Cell Carcinoma (NSCLC) category, Adenocarcinoma (ADC) represents the most common type, with different reported driver mutations, a bunch of models described and therapeutic options. Meanwhile, Pulmonary Sarcomatoid Carcinoma (PSC) is one of the rarest, with very poor outcomes, scarce availability of patient material, no effective therapies and no models available for preclinical research. Here, we describe that the combined deletion of Pten and Trp53 in the lungs of adult conditional mice leads to the development of both ADC and PSC irrespective of the lung targeted cell type after naphthalene induced airway epithelial regeneration. Although this model shows long latency periods and incomplete penetrance for tumor development, it is the first PSC mouse model reported so far, and sheds light on the relationships between ADC and PSC and their cells of origin. Moreover, human ADC show strong transcriptomic similarities to the mouse PSC, providing a link between both tumor types and the human ADC.

show abstract

New Therapeutic Strategies for Lung Cancer

Abstract: Non-small cell lung cancer (NSCLC) accounts for approximately 27% of all cancer-related deaths worldwide, thus representing a major health problem [...]

Cited by 7 publications

References 12 publications

A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer

A Systematic Role of Metabolomics, Metabolic Pathways, and Chemical Metabolism in Lung Cancer

Therapeutic Implications of PTEN in Non-Small Cell Lung Cancer

Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma

Contact Info

Product

Resources

About